United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/534,665	11/21/2005	Pratibhash Chattopadhyay	FER-14858.001.001	6541	
7609	7590 11/24/2006		EXAMINER		
RANKIN, HILL, PORTER & CLARK, LLP 925 EUCLID AVENUE, SUITE 700 CLEVELAND, OH 44115-1405			KENNEDY,	KENNEDY, SHARON E	
			ART UNIT	PAPER NUMBER	
			1615		

DATE MAILED: 11/24/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)	_			
	10/534,665	CHATTOPADHYAY ET AL.				
Office Action Summary	Examiner	Art Unit	_			
	Sharon E. Kennedy	1615				
The MAILING DATE of this communication Period for Reply	appears on the cover sheet w	th the correspondence address				
A SHORTENED STATUTORY PERIOD FOR REWHICHEVER IS LONGER, FROM THE MAILING - Extensions of time may be available under the provisions of 37 CFI after SIX (6) MONTHS from the mailing date of this communication - If NO period for reply is specified above, the maximum statutory pe - Failure to reply within the set or extended period for reply will, by st Any reply received by the Office later than three months after the mearned patent term adjustment. See 37 CFR 1.704(b).	B DATE OF THIS COMMUNI R 1.136(a). In no event, however, may a riod will apply and will expire SIX (6) MON atute, cause the application to become Al	CATION. eply be timely filed ITHS from the mailing date of this communication. BANDONED (35 U.S.C. § 133).				
Status						
1) Responsive to communication(s) filed on _						
,	This action is non-final.					
3) Since this application is in condition for allo		ers, prosecution as to the merits is				
•	closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims						
4)⊠ Claim(s) <u>1-20</u> is/are pending in the application.						
• • • • • • • • • • • • • • • • • • • •	4a) Of the above claim(s) is/are withdrawn from consideration.					
5) Claim(s) is/are allowed.						
6)⊠ Claim(s) <u>1-20</u> is/are rejected.						
7) Claim(s) is/are objected to.	•					
8) Claim(s) are subject to restriction ar	nd/or election requirement.					
Application Papers						
9) The specification is objected to by the Exan	niner.					
10)⊠ The drawing(s) filed on 11 May 2005 is/are:	10)⊠ The drawing(s) filed on 11 May 2005 is/are: a)⊠ accepted or b)□ objected to by the Examiner.					
Applicant may not request that any objection to						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11) ☐ The oath or declaration is objected to by the	e Examiner. Note the attache	d Office Action or form PTO-152.				
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for fore a) All b) Some * c) None of: 1. Certified copies of the priority docum 2. Certified copies of the priority docum 3. Copies of the certified copies of the papplication from the International Bu * See the attached detailed Office action for a	nents have been received. nents have been received in A priority documents have been reau (PCT Rule 17.2(a)).	pplication No received in this National Stage				
Attachment(s) 1) Notice of References Cited (PTO-892)	4) 🔲 Interview	Summary (PTO-413)				
2) Notice of Draftsperson's Patent Drawing Review (PTO-948	Paper No	s)/Mail Date				
3) Notice of Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date 05/03/2006. 5) Notice of Informal Patent Application 6) Other:						

DETAILED ACTION

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action or the MPEP.

Claim Rejections - 35 USC § 102

Claims 1-20 are rejected under 35 U.S.C. 102(b) as being clearly anticipated by Manning et al., US 5,770,559. Manning discloses the solubilization of pharmaceuticals using a supercritical gas antisolvent such as carbon dioxide. The pharmaceutical is solubilized in an organic solvent in conjunction with an amphiphilic material which anticipates the claims one or more solutes dissolved in one or more solvents. This combination forms a complex having a continuous phase (note column 5, lines 4-13, a continuous liquid phase is formed). Regarding the spray processes, see column 12, lines 43+. The particle sizes are disclosed in column 13, lines 50-60. The medicinal agents are disclosed in column 5, lines 40+. The organic solvents are disclosed in column 7, lines 1+.

Contact Information

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sharon E. Kennedy whose telephone number is 571/272-4948. The examiner can normally be reached on Monday-Thursday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Woodward, can be reached on 571/272-8373.

Application/Control Number: 10/534,665 Page 3

Art Unit: 1615

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Sharon Kennedy
Sharon E. Kennedy
Primary Examiner
Art Unit 1615